Cancer detection rate of Abbreviated (Fast) Breast MRI (AB-MR) after negative Digitial Breast Tomosynthesis in Women status post Conservation Therapy (BCT)
Enrolling By Invitation
99 years or below
All
500 participants needed
1 Location
Brief description of study
Women treated for primary breast cancer who undergo breast conservation therapy face an increased risk of developing a second breast cancer in the ipsilateral and the contralateral breast. Although mammographic screening is recommended annually, the sensitivity of mammography is limited in these patients due to the post treatment changes from previous surgery and radiation. We propose supplemental screening with an abbreviated form of breast MRI ("fast MRI") examination in addition to mammographic screening, in order to study whether we can detect subclinical disease that may not be detected on mammography or on physical examination. Several tumor characteristics correlate with overall survival such as the extent of local recurrence and the size of the local recurrence, with larger extent and increased size of local recurrence correlating with adverse survival. In addition, the shorter time interval to the ipsilateral breast cancer recurrence from completion of treatment, is associated with increased risk of developing distant metastasis and breast cancer mortality. We will assess additional cancer detection with fast MRI after negative mammography in the ipsilateral as well as the contralateral breast. The goal of the supplemental screening with fast breast MRI would be to detect subclinical disease not detected on mammography and thus improve patient outcomes.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Breast Neoplasms | Carcinoma, Intraductal, Noninfiltrating
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 829400
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245